title: Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
abstract: BACKGROUND
  To improve proton pump inhibitor effects, pharmacological modifications have been developed such as the use of enantiomer molecules (e.g., S-omeprazole, S-pantoprazole, or dexlansoprazole), or addition of NaHCO3 (for an immediate release) or magnesium (with a lower absorption for a more sustained effect).
  
  
  OBJECTIVE
  The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients.
  
  
  METHODS
  A phase IV, open-label, prospective, multicenter study was designed. Patients included were prescribed pantoprazole magnesium 40 mg orally once daily for 28±2 days. All patients had a history of persistent or recurrent heartburn and/or acid regurgitation for at least 3 months. Effectiveness and tolerability data obtained from patients who completed a minimum of 4 weeks of pantoprazole magnesium treatment were considered for analysis.
  
  
  RESULTS
  The account of baseline characteristics and demographics of GERD symptom intensity was made by analyzing the group of 4,343 patients that fulfilled all inclusion criteria; 54% were females (n=2,345) and 46% (n=1,998) males, with a mean age of 36.2±7.5 years. Severity of symptoms, assessed by the physician using the 4-point Likert scale, reduced by at least 80% from baseline intensity after treatment in the per protocol population. In the case of the intention-to-treat population, the improvement in symptom intensity was 73%. The number of patients that experienced any adverse events was 175/5,027 (3.48%).
  
  
  CONCLUSIONS
  Pantoprazole magnesium is a safe, effective, and well-tolerated drug that significantly improves GERD symptoms.
authors.affiliation: Digestive Physiology and Motility Lab, Instituto de Investigaciones Médico Biológicas, Universidad Veracruzana, Iturbide SN. Col Centro, Veracruz, VER, 91400, Mexico, jose.remes.troche@gmail.com.
authors.forename: José María
authors.initials: JM
authors.lastname: Remes-Troche
authors.forename: Sergio
authors.initials: S
authors.lastname: Sobrino-Cossío
authors.forename: Julio César
authors.initials: JC
authors.lastname: Soto-Pérez
authors.forename: Oscar
authors.initials: O
authors.lastname: Teramoto-Matsubara
authors.forename: Miguel
authors.initials: M
authors.lastname: Morales-Arámbula
authors.forename: Antonio
authors.initials: A
authors.lastname: Orozco-Gamiz
authors.forename: José Luis
authors.initials: JL
authors.lastname: Tamayo de la Cuesta
authors.forename: Gualberto
authors.initials: G
authors.lastname: Mateos
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006356:Heartburn / Q000188:drug therapy; D006801:Humans; D008297:Male; D000077402:Pantoprazole; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D012492:Salts; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D012492:Salts; D000077402:Pantoprazole